Clinical Trial Update: MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial update for MORAb-004 in young patients with recurrent or refractory solid tumors or lymphoma; the study has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Extranodal Nk T-cell Lymphoma Nasal Type
• Follicular Lymphoma
• Hodgkin Lymphoma
• Mantle Cell Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• MORAb-004

Snippet

Sponsor: Morphotek | Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Status: COMPLETED